A22-301
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
PharmaEssentia USA Corporation
Start Date
July 17, 2023
End Date
July 14, 2028
Administered By
Duke Cancer Institute
Awarded By
PharmaEssentia USA Corporation
Start Date
July 17, 2023
End Date
July 14, 2028